Take care for women at middle-aged or older who want to undergo estrogen therapy, as based on a recent study this therapy may be able to increase the risk of kidney stones in postmenopausal women.
For this study, researchers looked at data from postmenopausal women in the United States, collected from two studies titled Women's Health Initiative.
One study involving 10,739 women who had undergone hysterectomy, and those undergoing treatment of estrogen alone or placebo and followed for an average of 7 years.
While other studies included 16,608 women without hysterectomy who underwent either estrogen plus progestin therapy or placebo, and they were followed for an average of 5 years.
There were 335 reported cases of kidney stones in women on estrogen therapy group and 284 cases in the placebo group, the researchers said.
The incidence rate of kidney stones symptoms per year per 10,000 women a year was 39 on estrogen therapy group and 34 in the placebo group, according to study results published in the journal Archives of Internal Medicine.
The growth of the symptoms are five times more common in women with a history of kidney stones at baseline, but the growth of the symptoms was not significantly changed by estrogen therapy, said Dr. M. Naim Maalouf, from the University of Texas Southwestern Medical Center at Dallas.
The researchers found no significant relationship between the growth of the symptoms by age, ethnicity, body mass index (BMI), and previous hormone therapy, consumption of coffee or use of thiazide diuretics.
These findings suggest that estrogen therapy increases the risk of kidney stones in healthy postmenopausal women. The mechanism underlying this higher propensity remains to be determined.
Given the considerable prevalence of kidney stones in this population segment between 5 percent to 7 percent in the United States then the findings need to be considered in the decision making process associated with estrogen use in postmenopausal women.
For this study, researchers looked at data from postmenopausal women in the United States, collected from two studies titled Women's Health Initiative.
One study involving 10,739 women who had undergone hysterectomy, and those undergoing treatment of estrogen alone or placebo and followed for an average of 7 years.
While other studies included 16,608 women without hysterectomy who underwent either estrogen plus progestin therapy or placebo, and they were followed for an average of 5 years.
There were 335 reported cases of kidney stones in women on estrogen therapy group and 284 cases in the placebo group, the researchers said.
The incidence rate of kidney stones symptoms per year per 10,000 women a year was 39 on estrogen therapy group and 34 in the placebo group, according to study results published in the journal Archives of Internal Medicine.
The growth of the symptoms are five times more common in women with a history of kidney stones at baseline, but the growth of the symptoms was not significantly changed by estrogen therapy, said Dr. M. Naim Maalouf, from the University of Texas Southwestern Medical Center at Dallas.
The researchers found no significant relationship between the growth of the symptoms by age, ethnicity, body mass index (BMI), and previous hormone therapy, consumption of coffee or use of thiazide diuretics.
These findings suggest that estrogen therapy increases the risk of kidney stones in healthy postmenopausal women. The mechanism underlying this higher propensity remains to be determined.
Given the considerable prevalence of kidney stones in this population segment between 5 percent to 7 percent in the United States then the findings need to be considered in the decision making process associated with estrogen use in postmenopausal women.
0 comments:
Post a Comment